Immunovant won't seek approval for autoimmune drug despite phase 3 win
A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis or chronic inflammatory demyelinating polyneuropathy.
A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis or chronic inflammatory demyelinating polyneuropathy.
